You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

Article info

Article menu

Download PDFPDF

Case Report
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy

Authors

  1. ↵a Jose.sandoval{at}moffitt.org
  2. ↵b Fmogollo{at}health.usf.edu
  3. ↵c Ankita.patel{at}moffitt.org
  4. ↵d Nviswesh{at}health.usf.edu
  5. ↵e Damian.laber{at}moffitt.org
  6. ↵f Richard.kim{at}moffitt.org
  7. ↵g Michael.jaglal{at}moffitt.org
View Full Text

Citation

Sandoval-Sus JD, Mogollon-Duffo F, Patel A, et al
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy
Journal for ImmunoTherapy of Cancer 2017;5:49. doi: 10.1186/s40425-017-0252-3

Publication history

  • Received March 28, 2017
  • Accepted May 26, 2017
  • First published June 20, 2017.
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.